Business Wire

CA-GUIDEWIRE-SOFTWARE

16.6.2020 14:57:09 CEST | Business Wire | Press release

Share
Guidewire Reimagines Insurance Core Platforms with Aspen Release

Guidewire Software, Inc. (NYSE: GWRE), the platform P&C insurers trust to engage, innovate, and grow efficiently, today announced the launch of Aspen 2020.1H, featuring the first cloud-optimized release of Guidewire InsuranceSuite, and additional enhancements to Guidewire Analytics and Guidewire for Salesforce. Aspen1 extends support for insurers’ imperatives to unlock business and IT agility for accelerated product launches, personalized digital experiences, and embedded analytics throughout the insurance lifecycle.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005534/en/

Insurers around the world are focused on digitally engaging with customers and agents and making insurance more convenient. They need to innovate and launch new insurance products quickly and iterate them in market. Insurers must also grow their business efficiently by continuously measuring performance and testing process improvements. These goals typically require complex IT projects with insurers facing execution challenges due to a lack of IT agility. With Aspen, Guidewire delivers a cloud-optimized platform that delivers the agility insurers need to meet their business imperatives.

“The P&C insurance industry continues to evolve rapidly, and insurers, now more than ever, need the ability to quickly react and respond to market changes and needs,” said Karlyn Carnahan, head of Celent’s Property and Casualty practice for the Americas. “Cloud-optimized, digital-first platforms are the way of the future and will empower insurers to be competitive, reduce costs, and provide high levels of customer service, while increasing flexibility and agility.”

“For more than 18 years we have been dedicated to addressing the core system requirements of the P&C industry and today we are excited to announce a new approach,” said Mike Rosenbaum, chief executive officer, Guidewire. “Aspen is a significant milestone in our cloud journey and is arguably the most pivotal release in Guidewire’s history. It marks a redefinition in what we mean when we say core platform . Insurers expect that a core platform should do more than just run their core business processes. It also needs to be inherently connected to digital interfaces, take advantage of analytics capabilities, and be able to integrate data from any source. This is why we are unifying digital, analytics, and the core into one platform delivered in Guidewire Cloud.”

“Aspen is our first bi-annual cloud-optimized release that will bring customers even more IT agility, allowing them to get more value from their investment by laying the foundation for continuous improvement and future innovations,” said Diego Devalle, global head, Product and Engineering, Guidewire. “Beginning with the rating, rules, and data cloud-native services found in Aspen and continuing with subsequent releases, we will deliver a new generation of products that leverages cloud services architecture, and will continue building an open platform leveraging APIs.”

Aspen has been designed to bring agility to P&C insurers like never before to support their key imperatives:

Innovate

Aspen helps insurers create new products in days not months, analyze performance, and iterate at the speed of the market with reduced reliance on IT. Insurers can:

  • Accelerate product launches with Advanced Product Designer, a business-user friendly tool with visual, low-code configuration, while streamlining collaboration and design efforts.
  • With Guidewire Cloud, IT can stay current forever, rather than having to implement costly infrastructure upgrades. With fast cadence upgrades, IT will have access to two updates a year, allowing insurers to frequently consume new innovation and product capabilities.
  • Embrace and conquer new and evolving risks through Cyence risk insights that leverage petabytes of data on behavioral, social, and environmental signals so insurers can differentiate risk, automate underwriting, and make smarter pricing and risk selection decisions.

Engage

The release enables insurers to automatically create digital experiences that can easily be customized to serve all their customer segments. It allows them to:

  • Personalize digital experiences with the auto-generation of digital screens directly in PolicyCenter leveraging Advanced Product Designer for visual product definitions to help insurers best serve all of their customer segments.
  • Enable a unified and holistic customer view with Guidewire for Salesforce due to its ability to power insight-driven interactions with claims and policy service data, auto-generate quote and buy experiences, and allow sales and service teams to sell and service policies.
  • Deploy Cyence for Personal Cyber for on-demand, personalized cybersecurity assessments that include custom remediation recommendations to help users reduce their cyber risk.

Grow Efficiently

Aspen empowers insurers to leverage Guidewire Analytics powered by Guidewire Data Platform and Cyence to uncover hidden opportunities and write profitable business with a seamless path from data to value. The release enables insurers to:

  • Obtain data (including all intra-daily changes) from core systems in real-time via Cloud Data Access, a service of Guidewire Data Platform, and gain a competitive edge through Cyence data listening, to support their enterprise-wide data and analytics strategy.
  • Leverage embedded predictive analytics in core workflows to optimize operations and improve underwriting profitability.

About Guidewire

Guidewire is the platform P&C insurers trust to engage, innovate, and grow efficiently. ​We combine digital, core, analytics, and AI to deliver our platform as a cloud service. As of the end of our fiscal year 2019, more than 380 insurers, from new ventures to the largest and most complex in the world, run on Guidewire. ​

As a partner to our customers, we continually evolve to enable their success. We are proud of our unparalleled implementation track record, with 1,000+ successful projects, supported by the largest R&D team and partner ecosystem in the industry. Our marketplace provides hundreds of applications that accelerate integration, localization, and innovation.

For more information, please visit www.guidewire.com and follow us on twitter: @Guidewire_PandC .

NOTE: For information about Guidewire’s trademarks, visit https://www.guidewire.com/legal-notices .

All products mentioned in this announcement are Guidewire products.

1 Not all products are available in every geography or to self-managed customers. Guidewire customers can get more information from their Account Executive.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the future release schedule for Guidewire InsuranceSuite, Guidewire’s commitment to cloud services architecture for future products development, and general availability of products mentioned in this release. Forward-looking statements include those preceded by, followed by or that include the words “will,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “plans,” “estimates,” “targets,” “projects,” “intends” or similar expressions. Such forward-looking statements are subject to risks, uncertainties and other factors which could cause actual results to differ materially from historical experience or from future results expressed or implied by such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the impact of the COVID-19 pandemic on our employees and our business and the businesses of our customers, system integrator partners, and vendors; our reliance on sales to and renewals from a relatively small number of large customers for a substantial portion of our revenue; our ability to successfully manage any changes to our business model, including the transition of our products to cloud offerings and the costs related to cloud operations; intense competition in our market; weakened global economic conditions may adversely affect the P&C insurance industry including the rate of information technology spending; and other factors detailed in Guidewire’s most recent Form 10-Q filed with the Securities and Exchange Commission. Guidewire undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Guidewire’s views as of any date subsequent to the date of this press release.

Link:

ClickThru

Social Media:

https://www.facebook.com/guidewiresoftware

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye